Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 52-Week High After Analyst Upgrade

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) shares reached a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $170.00 to $235.00. Wells Fargo & Company currently has an overweight rating on the stock. Jazz Pharmaceuticals traded as high as $171.30 and last traded at $169.20, with a volume of 695559 shares. The stock had previously closed at $141.07.

JAZZ has been the subject of several other research reports. Truist Financial upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a report on Monday. JPMorgan Chase & Co. dropped their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Finally, Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.07.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Krensavage Asset Management LLC raised its position in Jazz Pharmaceuticals by 1.8% in the 3rd quarter. Krensavage Asset Management LLC now owns 167,816 shares of the specialty pharmaceutical company’s stock valued at $22,118,000 after buying an additional 3,000 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 35,106 shares of the specialty pharmaceutical company’s stock worth $4,527,000 after acquiring an additional 181 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Jazz Pharmaceuticals by 710.7% in the third quarter. Woodline Partners LP now owns 264,968 shares of the specialty pharmaceutical company’s stock valued at $34,923,000 after purchasing an additional 232,284 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Jazz Pharmaceuticals by 1.0% in the third quarter. Alyeska Investment Group L.P. now owns 205,954 shares of the specialty pharmaceutical company’s stock valued at $27,145,000 after purchasing an additional 2,086 shares during the last quarter. Finally, Quantessence Capital LLC acquired a new position in Jazz Pharmaceuticals during the third quarter worth $212,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

The firm has a market cap of $10.97 billion, a price-to-earnings ratio of -26.82, a PEG ratio of 8.49 and a beta of 0.29. The company’s fifty day moving average is $135.92 and its 200 day moving average is $121.19. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the previous year, the firm posted $6.54 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.